Keynote: COVID-19 overview, timeline, and key events T. Welte (Hannover, Germany)
|  |
COVID-19 epidemiology and prevention: Global update N. Shindo (Genève, Switzerland)
|  |
COVID-19: Lessons learnt from pandemic response P. Penttinen (Stockholm, Sweden)
|  |
COVID-19 epidemiology and prevention: Discussion, questions and answers
|  |
COVID-19: Vaccines – what are they and how do they work (current and trials) R. Boyton (London, United Kingdom)
|  |
Regulatory status of COVID-19 vaccines M. Cavaleri (Amsterdam, Netherlands)
|  |
Management of COVID-19: Drugs anti-virals J. Beigel (Baltimore, United States of America)
|  |
Management of COVID-19: Drugs anti-inflammatories F. Blasi (Milan, Italy)
|  |
Management of COVID-19: Other drugs and convalescent plasma M. Patout (Mont-Saint Aignan, France)
|  |
Management of COVID-19: Discussion, questions and answers
|  |
Management of COVID-19: Respiratory support (pre-ventilation, ventilation and ECMO) P. Navalesi (Padova, Italy)
|  |
Management of COVID-19: Palliative care D. Janssen (Horn, Netherlands)
|  |
Patient view: Acute COVID-19 experiences R. van der Made (Doorn, Netherlands), A. Sajnic (Zagreb, Croatia), S. Schiza (Heraklion, Greece)
|  |
Patient view on COVID-19: Shielding and interactions with other lung diseases Susannah Lindey, S. Schiza (Heraklion, Greece)
|  |
Patient view: Long COVID S. Williams (Limerick, Ireland), A. Sajnic (Zagreb, Croatia)
|  |
Patient view on COVID-19: Vaccines S. Williams (Limerick, Ireland), R. van der Made (Doorn, Netherlands)
|  |
Patient view on COVID-19: Positive outcomes S. Schiza (Heraklion, Greece), A. Sajnic (Zagreb, Croatia), S. Williams (Limerick, Ireland), S. Lindey (Roslin, United Kingdom), R. van der Made (Doorn, Netherlands)
|  |
Patient view on COVID-19: Discussion, questions and answers
|  |
Cardiovascular diseases and COVID-19 A. Lyon (London, United Kingdom)
|  |
Respiratory diseases and COVID-19 S. Aliberti (Milano, Italy)
|  |
COVID-19: Impact in adult patients with premorbid disease: Metabolic diseases (diabetes, obesity) W. Randerath (Solingen, Germany)
|  |
Paediatrics and COVID-19 A. Zacharasiewicz (Vienna, Austria)
|  |
Immunology: the immune response to mild and asymptomatic natural infection with SARS-CoV-2, and vaccination in healthy adults R. Boyton (London, United Kingdom)
|  |
Long COVID: Impact on the lung F. Blasi (Milan, Italy)
|  |
Long COVID: Impact on the heart B. Raman (Oxford, United Kingdom)
|  |
Long COVID: Neurological long-term effects G. Plazzi (Bologna, Italy)
|  |
Long COVID: Rehabilitation recovery S. Singh (Leicester, United kingdom)
|  |
Long COVID: Discussion, questions and answers
|  |
Keynote: Big data, machine learning and AI for COVID-19 M. Topalovic (Leuven, Belgium)
|  |
Big data, machine learning and AI for COVID-19: Discussion, questions and answers
|  |
Application of big data technology for COVID-19: Health economics of COVID K. Hauck (London, United Kingdom)
|  |
Application of big data technology for COVID-19: Primary care big data A. Sheikh (Edinburgh, United Kingdom)
|  |
ISARIC coronavirus clinical characterisation consortium C. Semple (Liverpool, United Kingdom)
|  |
CAD4COVID (Thirona): artificial intelligence solutions for CT- and X-ray analysis E. Van Rikxoort (Nijmegen, Netherlands)
|  |
DRAGON federated machine learning system S. Walsh (Liège, Belgium)
|  |
Application of big data technology for COVID-19: Panel discussion
|  |